FDA Regulatory Gaps in Excipient Disclosure
Active ingredients account for just 5-10% of a drug's weight. The remaining 90-95% consists of excipients. The FDA's disclosure requirements for these ingredients have significant gaps that leave patients in the dark.
How Drug Labeling Works Today
The FDA requires active ingredient disclosure on all medication labels. These are the therapeutic compounds that treat your condition. But they typically make up just 5-10% of a tablet or capsule's total weight.
The rest is excipients: binders that hold the tablet together, coatings that make it easy to swallow, preservatives that extend shelf life, dyes that identify the product. The FDA has approved roughly 200 excipients through its Inactive Ingredient Guide (IIG), but the actual number used in practice is much higher due to variants, blends, and proprietary formulations.
Excipients are required to appear on the physical label. But the requirements for how they appear, how they are categorized, and how they are reported electronically are far less rigorous than what the food industry has been doing for decades.
The Excipient Disclosure Gap
The food industry is required by law (FALCPA and the FASTER Act) to clearly declare major allergens on packaging. You see "Contains: milk, wheat, soy" on food labels because the law demands it. No equivalent requirement exists for medications.
Food Labeling
- ✓"Contains: milk, wheat, soy"
- ✓"May contain traces of peanuts"
- ✓Plain-language allergen declarations
- ✓Standardized format patients can scan
Drug Labeling
- ✗No allergen summary line
- ✗No "may contain" warnings
- ✗Technical names only (e.g. "lactose monohydrate")
- ✗No standardized format
This means a patient with a dairy allergy sees "lactose monohydrate" on their medication label and must know that lactose is a dairy derivative. There is no "Contains: dairy" line to help them. A patient avoiding corn must recognize that "pregelatinized starch," "dextrose," "maltodextrin," and "dextrates" are all corn-derived. The burden of knowledge falls entirely on the patient.
Physical Labels vs. Electronic Records
The FDA maintains two parallel systems for drug information: the physical label (what is printed on the box or bottle) and the electronic Structured Product Labeling (SPL) submission that manufacturers file digitally.
In theory, both should contain the same information. In practice, electronic submissions are not audited for completeness. The FDA accepts the filing and moves on. There is no automated check that verifies the electronic record matches the physical label.
This matters because every digital tool that patients, pharmacists, and doctors rely on is built on the electronic record. Pharmacy dispensing systems, clinical decision support tools, and databases like AllergenMaps all inherit whatever is in the SPL submission. If the electronic record is incomplete, every downstream system is wrong.
To compensate for these gaps, AllergenMaps cross-references multiple official FDA data sources and applies proprietary quality checks to catch discrepancies. But patients should not have to depend on a third-party tool to get accurate ingredient information.
Store Brands and Data Quality
A store-brand ibuprofen listing 15 ingredients on the box may appear in the FDA's electronic database with just one entry: "WATER." This is not a glitch. It is a gap in enforcement.
While building AllergenMaps, we discovered a systemic problem with store-brand medications from major big-box retailers. Their electronic FDA filings consistently underreport ingredients.
The physical box lists the full formula. But the electronic submission that powers every digital healthcare tool? Often just one or two ingredients. This is not technically illegal. The FDA requires the physical label to be complete, but enforcement of electronic filing completeness is minimal.
The consequence: any digital tool that relies on FDA electronic data will show these store-brand products as nearly allergen-free when they are not. This disproportionately affects cost-conscious patients who buy generics and store brands to save money.
The Spelling Problem
FDA electronic filings contain thousands of typos. There is no spell-check, no validation at submission time, and no automated correction after the fact.
Examples We Found
- Transposed letters in common ingredient names
- Truncated names that cut off mid-word
- The same ingredient spelled three different ways across products from the same manufacturer
Why does this matter? Automated systems that match ingredients to allergen categories fail on misspelled entries. If "CORN STARCH" is in the allergen database but the manufacturer typed "CORN STARTCH," a corn-allergic patient gets no warning.
AllergenMaps handles this with a proprietary standardization system and expert review that catches misspellings and maps them to the correct canonical ingredient. But this is a workaround for a problem that should not exist.
How Other Countries Handle This
The United States has one of the weakest excipient disclosure regimes among major pharmaceutical regulatory bodies.
European Union (EMA)
The European Medicines Agency requires excipients of "known effect" to be labeled with specific patient warnings. The Annex to the Guideline on Excipients maintains a list of excipients (including lactose, aspartame, and sodium) that require mandatory patient-facing warnings when present above threshold amounts.
Australia (TGA)
Australia's Therapeutic Goods Administration requires detailed excipient disclosure in Consumer Medicine Information (CMI) documents. Patients can access comprehensive ingredient breakdowns for any registered medication.
Japan (PMDA)
Japan's Pharmaceuticals and Medical Devices Agency requires detailed excipient labeling including source materials. If a starch is wheat-derived, that sourcing information must be disclosed.
What Needs to Change
These are achievable changes that would bring medication labeling in line with what the food industry has done for decades.
- 1Standardized electronic reporting with validation at submission time. Reject filings that are incomplete or contain obvious data quality issues.
- 2Allergen-specific labeling on medications matching food labeling requirements. A simple "Contains: dairy, corn" line on the label.
- 3Mandatory "may contain" warnings for drugs manufactured on shared equipment with common allergens.
- 4Source material transparency. If the starch is from corn or wheat, if the magnesium stearate is plant- or animal-derived, disclose it.
- 5Regular auditing of electronic SPL submissions against physical labels, with enforcement for discrepancies.
Until these changes happen, tools like AllergenMaps exist to fill the gap. But patients should not have to rely on a third-party database to know what is in their medication.